Chemometec A/S
CSE:CHEMM
Gross Margin
Chemometec A/S
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DK |
|
Chemometec A/S
CSE:CHEMM
|
9B DKK |
80%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
56%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
180.6B USD |
41%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
147.1B USD |
60%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
53%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.6B CHF |
37%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.7B USD |
35%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD |
54%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
256.7B CNY |
42%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.3B USD |
60%
|
|
| IN |
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
1.8T INR |
60%
|
Chemometec A/S
Glance View
Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Chemometec A/S's most recent financial statements, the company has Gross Margin of 80.1%.
You don't have any saved screeners yet